BioCentury | Sep 2, 2020
Management Tracks

Career officials Rebello, Felberbaum to lead FDA’s communications

Former FDA commissioners Scott Gottlieb and Robert Califf tweeted their praise Tuesday of the appointment of two long-time FDA officials to head the agency’s communications.  Heidi Rebello will become FDA’s acting associate commissioner for external...
BioCentury | Apr 1, 2020
Distillery Therapeutics

Targeting the NCK1-WIPF1 interaction for enteropathogenic E. coli infection

DISEASE CATEGORY: Infectious disease INDICATION: Escherichia A peptide that blocks the interaction between NCK1 and WIPF1 could treat or protect against enteropathogenic E. coli infection. A key step of infection involves binding of the SH3.2...
BioCentury | Nov 21, 2019

PGAM1 inhibition to treat pancreatic cancer

DISEASE CATEGORY: Cancer INDICATION: Pancreatic cancer Inhibiting the glycolysis enzyme PGAM1 could treat pancreatic cancer including pancreatic ductal adenocarcinoma (PDAC). In 50 PDAC patients, PGAM1 protein levels were higher in tumor tissue than in adjacent...
BioCentury | Nov 19, 2019

Reducing ER stress through USP14 inhibition could treat diabetes

DISEASE CATEGORY: Endocrine/metabolic INDICATION: Diabetes Targeting USP14 could treat Type II diabetes by reducing the effects of endoplasmic reticulum stress, which has been implicated in the disease’s pathogenesis. In lean mice, the ER stress inducer...
BioCentury | Aug 6, 2019
Financial News

IPD spinout Neoleukin merges with Aquinox for NASDAQ listing

Neoleukin thinks its merger with Aquinox announced Tuesday will enable the de novo protein design newco to submit an IND for its IL-2 mimetic and announce additional preclinical programs by the end of 2020. The...
BioCentury | Aug 2, 2019
Distillery Therapeutics

SH2B3 as a therapeutic target for melanoma

DISEASE CATEGORY: Cancer INDICATION: Melanoma Inhibition of SH2B3 could help treat melanoma. Levels of SH2B3 were higher in tumor samples from 12 patients than in samples of normal skin. In a mouse melanoma cell line,...
BioCentury | Mar 8, 2019
Emerging Company Profile

Janpix picks STAT inhibitors for blood cancers

Janpix is developing STAT3 and STAT5 inhibitors that could treat hematologic malignancies with greater durability and lower risk of side effects than other inhibitors of the JAK-STAT pathway. Janpix Inc. in-licensed its family of small...
BioCentury | Oct 4, 2018
Distillery Therapeutics


INDICATION: Anemia Cell culture and mouse studies suggest inhibiting SH2B3 could help treat FANCD2-deficient Fanconi anemia, a disorder involving loss of hematopoietic stem and progenitor cells (HSPCs). In FANCD2-deficient mouse HSPCs, SH2B3 knockout increased growth...
BioCentury | Jul 13, 2018
Company News

Aquinox halves workforce after sole clinical asset misses in Phase III

Aquinox Pharmaceuticals Inc. (NASDAQ:AQXP) said in an SEC filing it reduced headcount by 30 (53%) and halted all development of sole clinical asset rosiptor (AQX-1125) after the compound missed in a Phase III trial last...
BioCentury | Jun 29, 2018
Clinical News

Aquinox discontinues development of rosiptor

Aquinox Pharmaceuticals Inc. (NASDAQ:AQXP) said its sole clinical asset, rosiptor (AQX-1125), missed the primary endpoint in the double-blind, international Phase III LEADERSHIP 301 trial to treat interstitial cystitis/bladder pain syndrome (IC/BPS). The company said it...
Items per page:
1 - 10 of 122